Biotest AG
Biotest AG: Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic
DGAP-News: Biotest AG / Key word(s): Miscellaneous PRESS RELEASE Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic – Long-term plasma supplier Cara Plasma was taken over by Biotest – Biotest has now 16 plasma collection centres in Europe and – 22 stations in the USA for the strategic safeguarding of plasma supply
With Cara Plasma Biotest purchased a station in the Czech capital Prague and will further increase the plasma self-sufficiency rate. “The additional station in the Czech Republic gives us the opportunity to secure the supply for our production facilities with plasma. We are raising the good and trustworthy cooperation with our long-term partner and current supplier Cara Plasma to a new stage.” stated Dr. Martin Reinecke, Head of Plasma Alliances and Protein Supply. The collected plasma is processed exclusively at Biotest AG, Dreieich, Germany. Audits conducted regularly in the Czech Republic ensure that high legal and internal quality requirements are met. Biotest’s strategic goal is to increase the share of plasma from its own centres in the future. At the same time Biotest is striving for a balanced supply of plasma from Europe and the USA. About human blood plasma About Biotest IR contact PR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
19.07.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |